scholarly journals Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis

2021 ◽  
Vol 10 (20) ◽  
pp. 4693
Author(s):  
Alessio Martucci ◽  
Doriana Landi ◽  
Massimo Cesareo ◽  
Emiliano Di Carlo ◽  
Giovanni Di Mauro ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Posterior Pole ◽  
Optic Disk ◽  
Ophthalmological Examination ◽  
Complex Rearrangement ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Sd Oct

There are consolidated data about multiple sclerosis (MS)–dependent retinal neurodegeneration occurring in the optic disk and the macula, although it is unclear whether other retinal regions are affected. Our objective is to evaluate, for the first time, the involvement of the entire retinal posterior pole in patients diagnosed with relapsing remitting multiple sclerosis (RRMS) unaffected by optic neuritis using Spectral Domain–Optical Coherence Tomography (SD–OCT). The study protocol was approved by Tor Vergata Hospital Institutional Ethics Committee (Approval number 107/16), and conforms to the tenets of the Declaration of Helsinki. After a comprehensive neurological and ophthalmological examination, 53 untreated RRMS patients (aged 37.4 ± 10) and 53 matched controls (aged 36.11 ± 12.94) were enrolled. In addition, each patient underwent an examination of the posterior pole using the SD-OCT built-in Spectralis posterior pole scanning protocol. After segmentation, the mean thickness, as well as the thickness of the 64 single regions of interest, were calculated for each retinal layer. No statistically significant difference in terms of average retinal thickness was found between the groups. However, MS patients showed both a significantly thinner ganglion cell layer (p < 0.001), and, although not statistically significant, a thinner inner nuclear layer (p = 0.072) and retinal nerve fiber layer (p = 0.074). In contrast, the retinal pigment epithelium (p = 0.014) and photoreceptor layers p < 0.001) resulted significantly thicker in these patients. Interestingly, the analysis of the region of interest showed that neurodegeneration was non-homogeneously distributed across each layer. This is the first report that suggests a complex rearrangement that affects, layer by layer, the entire retinal posterior pole of RRMS retinas in response to the underlying neurotoxic insult.

scholarly journals A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year

1994 ◽  
Vol 21 (3) ◽  
pp. 266-270 ◽  
Author(s):  
S. Bastianello ◽  
C. Pozzilli ◽  
F. D’Andrea ◽  
E. Millefiorini ◽  
M. Trojano ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Gadolinium Dtpa ◽  
Treatment Groups ◽  
Number Of Patients ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
The Mean ◽  
Remitting Multiple Sclerosis ◽  
One Year ◽  
Relapsing Remitting Multiple Sclerosis

Abstract:We present the results of a randomized double-blinded placebo controlled, multicenter trial, of low-dose mitoxantrone (MX), after one year, in 25 patients with relapsing-remitting multiple sclerosis, who had serial enhanced magnetic resonance imaging (MRI). Treatment groups were balanced for age, gender, duration of illness and neurological disability. Five of the 13 MX patients and 10 of the 12 placebo patients had exacerbations during treatment (p < 0.02). The mean change in the extended disability status scale was not significantly different between the MX and placebo treatment groups. Serial Gadolinium-DTPA enhancedMRIdetected no significant difference between the MX treated and placebo groups in the mean total number of new, enlarging, or Gadolinium-DTPA enhancing lesions; there was a trend toward a reduction of new, enlarging and Gadolinium-DTPA enhancing lesions in MX patients. Despite this ameliorating effect, the results indicate that serial Gadolinium-DTPA enhanced MRI, performed over one year in a limited number of patients, could not provide conclusive evidence for a role of MX therapy in relapsing-remitting multiple sclerosis.

scholarly journals Attention impairment associated with relapsing-remitting multiple sclerosis patients with mild incapacity

2007 ◽  
Vol 65 (2A) ◽  
pp. 262-267 ◽  
Author(s):  
Silvia Balsimelli ◽  
Maria Fernanda Mendes ◽  
Paulo H.F. Bertolucci ◽  
Charles Peter Tilbery
Keyword(s):  
Multiple Sclerosis ◽  
Digit Span ◽  
Stroop Test ◽  
Central Processing ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Attention Impairment

Neuropsychological studies have consistently reported cognitive dysfunctions associated with multiple sclerosis. One-hundred fifteen subjects with relapsing-remitting multiple sclerosis (RRMS) were compared with forty health controls according to a neuropsychological test battery, which included digit span, trail making, cancellation and stroop test. Both groups were matched for age, sex and educational level. Subjects with RRMS had a worse performance the speed of response. Subjects with RRMS spent more time to complete the test in either sections A (p=0.001) or B (p=0.001), although there was no significant difference in terms of number of errors. The total time required to finish the Stroop test was higher for subjects with RRMS (p<0.001), being the time difference between groups significant at trial 4 (p<0.001). Attention impairment in subjects with RRMS is related to slowed central processing, which may be affected in all stages, including impairment of automatic and controlled processing of information and in the motor program.

Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy

2002 ◽  
Vol 8 (1) ◽  
pp. 15-18 ◽  
Author(s):  
J Reeß ◽  
J Haas ◽  
K Gabriel ◽  
A Fuhlrott ◽  
M Fiola
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Open Label ◽  
Treatment Groups ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Mild Impairment ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis

Interferon beta-1a is an established therapy for patients with relapsing-remitting multiple sclerosis (MS). Adverse effects in the first weeks of treatment are common. This open-label, multicenter, randomized, prospective study compared treatment of flu-like symptoms (FLS) with paracetamol versus ibuprofen administered 48 h within interferon injection. The percentage of patients with FLS was comparable between both treatment groups and improved during the course of the study (baseline: paracetamol 92%, ibuprofen 90%; week 12: paracetamol 60%, ibuprofen 57%). More than 75% of patients receiving either paracetamol or ibuprofen reported no or only mild impairment of daily activities. There was no significant difference in general satisfaction or incidence of additional symptoms (weakness, nausea, headache; paracetamol 84.6% patients, ibuprofen 86.0% patients) between the two groups. A significant overall improvement from baseline to week 12 was observed for all parameters studied (paracetamol and ibuprofen groups were pooled). These results indicate that neither the paracetamol nor the ibuprofen treatment regimen is better.

scholarly journals Longitudinal analysis of verbal episodic memory in patients with relapsing-remitting multiple sclerosis

2018 ◽  
Vol 76 (5) ◽  
pp. 302-309
Author(s):  
Izadora Nogueira Fonte Boa ◽  
Carolina de Medeiros Rimkus ◽  
Kenia Repiso Campanholo ◽  
Samira Luisa Apóstolos Pereira ◽  
Thiago de Faria Junqueira ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Episodic Memory ◽  
Statistical Difference ◽  
Control Group ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Neuropsychological Assessments ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Verbal Episodic Memory

ABSTRACT Objective: A 4.5-year follow-up study was conducted to characterize baseline verbal episodic memory (VEM) and its behavior and to assess the effects of relapsing-remitting multiple sclerosis (RRMS) on this domain. Methods: Twenty-nine patients with RRMS underwent two neuropsychological assessments performed an average of 4.5 years apart. Twenty-six control participants underwent a single neuropsychological assessment. A significance level of p < 0.005 was adopted to denote a significant difference between the groups on the Mann Whitney and Wilcoxon paired statistical analyses. Results: No statistical difference was found in the results of the VEM tests between the first and second neuropsychological assessments of the patients. However, a statistical difference was evident between the patient and control groups in the results of the VEM tests. Conclusion: The patient group showed changes in the VEM relative to the control group. After approximately 4.5 years of disease, the patient performance on the VEM stabilized or improved.

scholarly journals Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta

2020 ◽  
Author(s):  
Leila Karimi ◽  
Nahid Eskandari ◽  
Vahid Shaygannejad ◽  
Nasrin Zare ◽  
Alireza Andalib ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Th17 Cells ◽  
Interferon Beta ◽  
T Helper ◽  
Expression Levels ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Ifn Γ ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

T helper type 1 (Th1) and Th17 Cells with distinct cytokine profiles including interferon-gamma (IFN-γ) and interleukin 17 (IL-17) have a pivotal role in neuroinflammation and myelin destruction in the central nervous system (CNS) in MS. MicroRNA-29b (MiR-29b) and miR-326 contribute to regulating Th1 and Th17 differentiation and altered expression of the miRNAs could be associated with response to treatment in multiple sclerosis (MS). Therefore, our study aimed to evaluate the percentage of Th1 and Th17 and determining the expression levels of miR-29b-3p and miR-326 in these lymphocyte subpopulations between responsive and non-responsive to interferon beta (IFN-β) therapy in relapsing-remitting multiple sclerosis (RRMS) patients. The present study was performed on 40 RRMS patients following treatment with IFN-β. The percentage of Th1 cells and Th17 cells were determined by flow cytometry in responsive and nonresponsive patients. The expression levels of miR-29b-3p and miR-326 were assessed in Th1 and Th17 cells by quantitative polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) was applied to evaluate the plasma levels of IFN-γ and IL-17A. No significant difference was observed in the percentage of Th1 and Th17 cells as well as the expression levels of miR-29b-3p and miR-326 (in Th1 and Th17, respectively) in treated patients. Also, we did not find any significant difference in IFN-γ and IL-17A plasma concentration between responsive or non-responsive to IFN-β therapy in patients with RRMS. IFN-β may regulate other miRNAs in Th1 and Th17 cells than miR29b-3p and miR-326 in MS patients.

scholarly journals The effect of interferon-β therapy on brain-derived neurotrophic factor serum concentration in relapsing— remitting multiple sclerosis: a randomized clinical trial

2019 ◽  
Vol 5 (2) ◽  
pp. e14-e14
Author(s):  
Nastaran Majdinasab ◽  
Mohammad Bahadoram ◽  
Syed Mohammad Taghi Mansouri ◽  
Shahram Tarahomi ◽  
Fatemeh Javanmardi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trial ◽  
Serum Concentration ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Individual Response ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Introduction: Beta interferon (IFN-β) is known as the first-line therapy in relapsing-remitting multiple sclerosis (RRMS). Recent studies have shown different effects of IFN-β on brain-derived neurotrophic factor (BDNF) serum levels. Given the known role of BDNF in the restoration and conservation of the nervous system, this study was designed to investigate the possible effect of this drug through stimulating BDNF production. Objectives: Impressible treatments for progressive multiple sclerosis (MS) are still being sought. Individual response to existing treatments for MS varies significantly among patients while the risk of serious adverse events remains an issue, especially for the novel drugs. Patients and Methods: In this clinical trial, 96 patients newly diagnosed with RRMS were studied within three months, in 3 groups of 32 subjects. Each group received one of the foregoing drugs (Avonex, Rebif and Betaferon). BDNF levels were compared between different groups at the end. Results: BDNF serum concentration in all groups was significantly different (P<0.001) compared to baseline after 3 months. And comparison between groups showed a significant difference between the groups receiving Betaferon (IFN-β1b) (P=0.001) and Rebif (P=0.002) compared to the other groups. Avonex compared with either control or Betaferon (IFN-β1b) and Rebif groups showed no significant difference. Also the correlation between the mean changes in expanded disability status scale (EDSS) and BDNF was not observed (r = -0.189, P=0.065). Conclusions: Significant difference in BDNF levels were observed between groups.

057 Real world evidence (RWE) on long-term persistence of fingolimod in relapsing-remitting multiple sclerosis (RRMS) in australia

2018 ◽  
Vol 89 (6) ◽  
pp. A23.3-A24 ◽  
Author(s):  
Robert Walker ◽  
Mark Schulz ◽  
Birendra Arora ◽  
Eric Chung ◽  
Prabhjot Juneja ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Dimethyl Fumarate ◽  
Rank Test ◽  
P Values ◽  
Hazard Ratios ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

IntroductionThis study aimed to examine and compare patient persistence of fingolimod to all reimbursed disease modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) in Australia.MethodThe Pharmaceutical Benefits Scheme (PBS) 10% sample supplied by the Department of Human Services was used in this study. Eligible patients must have received a script for a reimbursed DMT for RRMS between September 2011 and February 2016. Patient demographics were summarised using mean and standard deviation or frequency percentage. Persistence was defined as a patient that remained on a DMT with a gap in scripts of no longer than 4 months. Individual patients could be included multiple times if they initiated a new DMT during the study period. Persistence was derived using the Kaplan-Meier method and hazard ratios (HR). Persistence to individual treatments was then compared to the average persistence observed across all treatments; p-values were based on the log-rank test.Results720 unique patients were eligible for the study, contributing 1827 observations that for analysis (2.5 new initiations/patient). Overall the median persistence (MP) to therapy was 29.6 months with 67.7% of patients remaining on therapy for 12 months. The only DMT with significantly better persistence compared to the overall average was fingolimod (HR 0.65 (95%CI 0.57–0.73; p<0.001). Patients had an MP of 60 months on fingolimod with 79.5% of patients persistent at 12 months. Patients were significantly less persistent to interferon Beta-1a, interferon Beta-1b, glatiramer acetate and dimethyl fumarate (hazard ratios above 1.27 (p values all≤0.001) whilst the remaining DMTs, teriflunomide and natalizumab, showed no significant difference from the average persistence.ConclusionIn this analysis of PBS sample data, patients were most persistent to fingolimod treatment amongst all DMTs.

Is Everything a Challenge for Multiple Sclerosis patients? Nonverbal Semantic Memory Performance in Iranian Relapsing-Remitting Multiple Sclerosis Patients

2021 ◽  
Vol 20 (2) ◽  
pp. 390-395
Author(s):  
Sara Yazdani ◽  
Shahla Sharifi ◽  
Mohsen Foroughipour ◽  
Atiyeh Kamyabi Gol
Keyword(s):  
Multiple Sclerosis ◽  
Reaction Time ◽  
Semantic Memory ◽  
Memory Performance ◽  
Medical Science ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis

Objectives: The objective of the current study was to evaluate the nonverbal semantic memory performance of MS patients and compare it with their healthy counterparts. Materials and methods: In this study, 70 patients with definite relapsing-remitting multiple sclerosis(15 men and 55 women) and 70 healthy individuals of comparable demographics (age, gender, and education) from patients’ relatives and family members were selected based on convenient sampling. The patients recruited for this study were divided into two groups based on their Montreal Cognitive Assessment (MoCA) scores. The first group of patients (MS1) with MoCA scores of 18-25, and the MoCA scores of the second group (MS2) ranged from 10 -17. All of the participants were right-handed, originally born in Mashhad, Iran, and native speakers of Persian. To assess the nonverbal semantic memory performance of the participants, the picture version of The Camel and Cactus Test (CCT) was selected and administered from the Cambridge Semantic Memory battery test. Results: The results revealed that there was no significant difference between the MS1 and the Healthy Controls group in living and man-made variables, while MS 2 performed significantly different compared to other groups in these variables. The results also showed that all three groups of participants performed significantly different from each other in reaction time variable. Conclusion: The findings showed that cognitive impairment in multiple sclerosis patients did not affect their nonverbal semantic memory performance, however, it had an impact on their reaction time. Bangladesh Journal of Medical Science Vol.20(2) 2021 p.390-395

Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-la (AVONEX®) therapy

2002 ◽  
Vol 8 (1_suppl) ◽  
pp. 15-18
Author(s):  
J. Reeß ◽  
J. Haas ◽  
K. Gabriel ◽  
A. Fuhlrott ◽  
M. Fiola
Keyword(s):  
Multiple Sclerosis ◽  
Interferon Beta ◽  
Open Label ◽  
Treatment Groups ◽  
Significant Difference ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Mild Impairment ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis

Interferon beta-la is an established therapy for patients with relapsing-remitting multiple sclerosis (MS). Adverse effects in the first weeks of treatment are common. This open-label, multicenter, randomized, prospective study compared treatment of flu-like symptoms (FLS) with paracetamol versus ibuprofen administered 48 h within interferon injection. The percentage of patients with FLS was comparable between both treatment groups and improved during the course of the study (baseline: paracetamol 92%, ibuprofen 90%; week 12: paracetamol 60%, ibuprofen 57%). More than 75% of patients receiving either paracetamol or ibuprofen reported no or only mild impairment of daily activities. There was no significant difference in general satisfaction or incidence of additional symptoms (weakness, nausea, headache; paracetamol 84.6% patients, ibuprofen 86.0% patients) between the two groups. A significant overall improvement from baseline to week 12 was observed for all parameters studied (paracetamol and ibuprofen groups were pooled). These results indicate that neither the paracetamol nor the ibuprofen treatment regimen is better. Multiple Sclerosis (2002) 8, 15-18

Sign in / Sign up

Export Citation Format

Share Document